This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Recombinant Equine Interleukin-13 (IL13), N-His
Product Overview
BioVenic's Recombinant Equine Interleukin-13 (IL13), N-His is a recombinant protein expressed from E.coli. Its predicted molecular weight is N/A. The purity is>97% (SDS-PAGE).
Specifications
Target Information
Equine interleukin-13 (IL-13) is a Th2 cell-derived cytokine with pleiotropic effects on immune responses, particularly in asthma, allergy, fibrosis, and eosinophilic disorders. It plays a role in B lymphocyte activation, immunoglobulin E (IgE) synthesis, and the promotion of an anti-inflammatory phenotype in macrophages. IL-13 is also implicated in the pathogenesis of autoimmune diseases, making it a promising therapeutic target for conditions such as lupus, rheumatoid arthritis, and inflammatory bowel diseases.
Shipping and Storage
This product is shipped with dry ice. It is recommended to aliquote as needed and store at -80°C upon receipt. Reconstituted protein solution can be stored at 4°C for 1 week, at < -80°C for 12 months.
Documents
The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.
User Note
- Always centrifuge tubes before opening. Avoid mixing by vortexing or pipetting. Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL.Aliquote the reconstituted solution to minimise freeze-thaw cycles.